The Lancet Gastroenterology & Hepatologyに中島クリニック院長共著論文がアクセプトされました。

世界で最も権威ある雑誌の一つであるランセットの消化器専門誌に論文掲載されました。

論文タイトル
「Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.」

世界初となる作用機序をもつSGLT1阻害薬の臨床効果の報告です。

SGLTにはサブタイプ(種類)があり、SGLT1は主に小腸上皮で発現しています。

ダブルブラインドで便秘型過敏性腸症候群（IBS-C)に有効性を示すことができました。新たな作用機序のIBS-C治療薬として臨床化が期待されるところです。

論文タイトル
【Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial】

論文著者
Fukudo S, Endo Y, Hongo M, Nakajima A, Abe T, Kobayashi H, Nakata T, Nakajima T, Sameshima K, Kaku K; Mizagliflozin Study Group.

掲載論文
Lancet Gastroenterol Hepatol. 2018 Sep;3(9):603-613. doi: 10.1016/S2468-1253(18)30165-1. Epub 2018 Jul 25.

要約
Abstract

BACKGROUND:

Mizagliflozin is a novel oral sodium-glucose cotransporter 1 (SGLT1) inhibitor that increases luminal glucose and water. This study assessed the efficacy and safety of mizagliflozin in patients with functional constipation.

METHODS:

In this multicentre, randomised, double-blind phase 2 trial at 32 hospitals and community outpatient clinics in Japan, we enrolled patients with functional constipation or constipation-predominant irritable bowel syndrome, aged 20 years or older. Patients were randomly assigned (1:1:1), by use of an independent centralised registration system and dynamic allocation method, to receive mizagliflozin 5 mg, mizagliflozin 10 mg, or placebo, orally once daily for 4 weeks. Patients, investigators, staff, and the sponsor were blinded to the group assignments. The primary outcome was the change from baseline in the number of spontaneous bowel movements per week after 1 week. Efficacy analysis was done in all patients except those who deviated from good clinical practice, did not receive at least one dose of the study drug, withdrew before starting treatment, were ineligible, or for whom the primary outcome could not be assessed, and safety was assessed in all patients except those who deviated from good clinical practice, who did not receive the study drug, or who withdrew before receiving treatment. This trial is registered with ClinicalTrials.gov, number NCT02281630, and is completed.

FINDINGS:

Between Oct 15, 2014, and March 7, 2015, 258 patients with functional constipation were randomly assigned: 86 patients per group. Two patients from the placebo group and three from the 10 mg mizagliflozin group were excluded because the primary outcome could not be assessed, and one patient from the 5 mg mizagliflozin group was excluded for not receiving the study drug; therefore 84 patients in the placebo group, 85 in the 5 mg mizagliflozin group, and 83 in the 10 mg mizagliflozin group were included in the full analysis population. Mean change from baseline in the number of spontaneous bowel movements per week after 1 week with mizagliflozin 5 mg (3·85 [SD 3·96]) and mizagliflozin 10 mg (5·85 [6·01]) was significantly greater than those in the placebo group (1·80 [1·80]; p<0·0001 for both comparisons). The most common adverse events were nasopharyngitis (one [1%] of 86 patients in the placebo group, seven [8%] of 85 on mizagliflozin 5 mg, and five [6%] of 86 on mizagliflozin 10 mg), diarrhoea (none on placebo, four [5%] patients on mizagliflozin 5 mg, and eight [9%] on mizagliflozin 10 mg), and abdominal distention (three [3%] on placebo, four [5%] on mizagliflozin 5 mg, and seven [8%] on mizagliflozin 10 mg). Only diarrhoea and abdominal distention were deemed to be related to mizagliflozin treatment, whereas nasophanyngitis might not be related to mizagliflozin treatment, on the basis of clinical evaluation.

INTERPRETATION:

The SGLT1 inhibitor mizagliflozin showed favourable efficacy and tolerability at 5 mg and 10 mg doses in patients with functional constipation, providing a potential alternative therapy to available drugs.

2018年8月2日(木）
CKD Up Date in 西宮
～慢性腎臓病予防連携について考える～
中島クリニック院長がオープニングリマークスで
「西宮市慢性腎臓病(CKD)重症化予防連携事業の枠組み、昨年10月開始以降の実施状況」について講演いたします。

シナリオ監修として関わらせていただいた 「医療通訳テキスト」がついに完成、厚生労働省のホームページに掲載されました。

「医療通訳」聞き慣れないことばですが、外国の方が母国語で医療をうけることができるようにサポートするのが医療通訳です。

私は、シナリオ、例文医学的チェック、単語対訳のチェック（英語部分）を担当させていただきました。

378ページの大作、企画から編集、装丁まで、多文化共生センターきょうとスタッフのみなさま本当にお疲れさまでした。

厚生労働省のホームページからダウンロードできます。
↓

「医療通訳育成カリキュラム基準　医療通訳テキスト」